First Patient Expected to be Dosed Next Week with Intranasal Foralumab; PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi ® (Lecanemab) A ...
After 25 years in private practice, he has returned to screenwriting with Baxter’s Brain, a satiric, irreverent, over the top comedy that pokes fun at doctors, TV shows, and “the insanity of our ...
Lorundrostat demonstrated a favorable safety and tolerability profile in the Launch-HTN trial, noting that while hyponatremia, hyperkalemia, and reduced kidney function occurred more frequently in the ...
The reverse stock split was approved by Intelligent Bio Solutions’ stockholders at the annual meeting of the Company’s stockholders held on October 16, 2025, with the final ratio to be determined by ...
The GMP batch was successfully produced using Zelluna’s proprietary manufacturing process, which was finalised and locked in April 2025. The process is designed to deliver high-quality TCR-NK products ...
Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility ...
Therapeutic Effects for AUD: Recreational users usually take MEAI orally in amounts ranging from 1 to 2 mg/kg body weight per session. They report feeling positive effects within 4 hours, including a ...
To support the conversion and fund its expanded commitments under the Joint Development structure, NewGen plans to raise additional funds. Any capital raised will further strengthen the Company’s ...
RadioMedix, Inc., a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and cancer therapy, today announced that they have entered into ...
Harold Health announced the official release of the Harold Health app, a dedicated telehealth platform designed exclusively for men and built to support both mental and physical well-being. The app ...
By integrating data across multiple studies, this analysis confirms that TissueCypher provides consistent, reproducible performance and supports its potential to help physicians deliver risk-aligned ...
The median progression free survival (PFS) was 10.3 months for all patients. Among the total of 31 patients with measurable disease, objective response rate (ORR) was 39%. For second line (2L) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback